DNA:NYSE
Ginkgo Bioworks Holdings Inc
$10.07
arrow_downward
-2.00%(-0.20) 1D
$10.02
arrow_downward
-0.50% (-0.051)bedtimeAfter hours
Closed: Oct 19, 4:00:03 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DNA...
Open
$10.38
High
$10.50
Low
$9.76
Mkt. cap
647.91M
Avg. vol.
2.94M
Volume
2.48M
52-wk high
$18.22
52-wk low
$5.37
EPS
-$5.00
Beta
1.79
Shares outstanding
55.38M
No. of employees
485
Open
$10.38
High
$10.50
Low
$9.76
Mkt. cap
647.91M
Avg. vol.
2.94M
Volume
2.48M
52-wk high
$18.22
52-wk low
$5.37
EPS
-$5.00
Beta
1.79
Shares outstanding
55.38M
No. of employees
485
News stories
From web sources and news partners
Investing.com India
·
2 hours ago
Form 144 Ginkgo Bioworks Holdings For: 19 October By Investing.com
Stock Titan
·
3 hours ago
A 766-share sale proposed by Ginkgo Bioworks (DNA) officer Steve Coen includes shares to cover taxes.
https://www.dars.gov.et/
·
1 week ago
DNA Q2 2026 Earnings: Narrower-Than-Expected Loss Beats Consensus, but Shares Slide 7.57%
Profile
Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It raised $290 million in September and $350 million in October of that year. Ginkgo Bioworks went public on the New York Stock Exchange via a SPAC merger on September 17, 2021. Wikipedia
About Ginkgo Bioworks Holdings Inc
CEOJason Kelly
Employees485
Founded2008
HeadquartersBoston, Massachusetts, United States
SectorHealth care
Websiteginkgo.bio